RS20070512A - Pharmaceutical sustained release compositionsand processes thereof - Google Patents

Pharmaceutical sustained release compositionsand processes thereof

Info

Publication number
RS20070512A
RS20070512A RSP-2007/0512A RSP20070512A RS20070512A RS 20070512 A RS20070512 A RS 20070512A RS P20070512 A RSP20070512 A RS P20070512A RS 20070512 A RS20070512 A RS 20070512A
Authority
RS
Serbia
Prior art keywords
sustained release
compositionsand
processes
pharmaceutical sustained
active agent
Prior art date
Application number
RSP-2007/0512A
Other languages
English (en)
Inventor
Rajesh JAIN
Kour Chand JINDAL
Sukhjeet Singh
Sanjay Boldhane
Original Assignee
Panacea Biotec Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027780&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20070512(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd., filed Critical Panacea Biotec Ltd.,
Publication of RS20070512A publication Critical patent/RS20070512A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nove farmaceutske smese sa zadržanim otpuštanjem koje sadrže bar jedno aktivno sredstvo(-a), ili njegove tautomerne oblike, analoge, izomere, polimorfe, solvate, ili njihove soli; pogodno je obezbeđeno antivirusno aktivno sredstvo. Takođe je obezbeđen postupak za dobijanje takvih kompozicija i metoda za njihovu upotrebu. Kompozicije sa zadržanim otpuštanjem ovog pronalaska imaju sposobnost da isporučuju aktivno sredstvo na željeni način u produženom vremenskom periodu.
RSP-2007/0512A 2005-06-29 2006-06-29 Pharmaceutical sustained release compositionsand processes thereof RS20070512A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1680DE2005 2005-06-29
PCT/IN2006/000225 WO2007000779A2 (en) 2005-06-29 2006-06-29 Pharmaceutical sustained release compositions and processes thereof

Publications (1)

Publication Number Publication Date
RS20070512A true RS20070512A (en) 2009-01-22

Family

ID=37027780

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2007/0512A RS20070512A (en) 2005-06-29 2006-06-29 Pharmaceutical sustained release compositionsand processes thereof

Country Status (15)

Country Link
US (1) US20090099154A1 (sr)
EP (1) EP1912628A2 (sr)
JP (1) JP2009500318A (sr)
CN (1) CN101212957A (sr)
AR (1) AR055070A1 (sr)
AU (1) AU2006263338A1 (sr)
BR (1) BRPI0613070A2 (sr)
CA (1) CA2613407A1 (sr)
CR (1) CR9705A (sr)
EA (1) EA200800162A1 (sr)
MX (1) MX2008000084A (sr)
NO (1) NO20080399L (sr)
RS (1) RS20070512A (sr)
TN (1) TNSN07490A1 (sr)
WO (1) WO2007000779A2 (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709606B8 (pt) 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
CN101489937B (zh) * 2006-06-08 2016-08-10 耶鲁大学 用于渗透性溶质回收的多级塔蒸馏(mscd)方法
JP5547966B2 (ja) * 2006-12-15 2014-07-16 カンピナ ネーデルランド ホールディング ビー．ブイ． 持続放出用の賦形剤及びその使用
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
US20100056493A1 (en) * 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same
EP2155169B1 (en) 2007-06-08 2016-03-23 Boehringer Ingelheim International GmbH Extended release formulation of nevirapine
CA2702904A1 (en) 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
BR112012019374B1 (pt) * 2010-02-03 2022-01-11 Pharma Two B Ltd Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas
WO2011117875A1 (en) * 2010-03-26 2011-09-29 Hetero Research Foundation Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
CN102058553B (zh) * 2010-12-28 2012-10-10 哈药集团三精制药股份有限公司 阿昔洛韦缓释片及其制备方法
JP5976657B2 (ja) * 2011-09-30 2016-08-24 持田製薬株式会社 易服用性固形製剤
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
AU2013235345B2 (en) 2012-03-21 2016-03-24 Galleon Labs Llc Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
WO2014181390A1 (ja) * 2013-05-08 2014-11-13 全星薬品工業株式会社 機能性高分子皮膜で被覆された高含量薬物粒子およびそれを含む錠剤ならびにそれらの製造方法
CN105611915B (zh) * 2013-08-14 2021-05-11 赢创运营有限公司 包衣组合物
WO2015048153A1 (en) * 2013-09-24 2015-04-02 Cosmederm Bioscience, Inc. Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus
CN103705933A (zh) * 2013-12-18 2014-04-09 北京科源创欣科技有限公司 奥卡西平药物组合物及制备方法
JP6532765B2 (ja) * 2014-06-06 2019-06-19 株式会社ファンケル 即効性成分と持続性成分を含む錠剤
PL3223797T3 (pl) 2014-11-26 2020-07-27 Evonik Operations Gmbh Kompozycja farmaceutyczna lub nutraceutyczna wykazująca odporność na wpływ etanolu
CN104666267B (zh) * 2015-03-27 2017-08-08 康普药业股份有限公司 一种阿昔洛韦药物组合物
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN106943356B (zh) * 2017-05-10 2019-11-08 武汉人福药业有限责任公司 一种泛昔洛韦缓释颗粒剂及其制备方法
JP6958856B2 (ja) * 2017-08-09 2021-11-02 日本臓器製薬株式会社 錠剤
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN109466152B (zh) * 2018-09-04 2021-01-26 浙江罗奇泰克科技股份有限公司 一种高导热铁基板的制作方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110880A (en) * 1991-01-30 1999-06-30 The Wellcome Foundation Ltd Water-dispersible tablets
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US20030134864A1 (en) * 1996-02-07 2003-07-17 Smithkline Beecham P.L.C. Activity of penciclovir against epstein-barr virus
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
NZ510487A (en) * 1998-09-14 2003-04-29 Ranbaxy Lab Ltd Pharmaceutical composition comprising ciprofloxacin, sodium alginate, xanthan gum and a cross-linker polymer in a tablet or capsule form
WO2002102415A1 (en) * 2001-06-18 2002-12-27 Blue Cross Laboratories Limited Gastric floating system
US20060159752A1 (en) * 2002-08-14 2006-07-20 Jain Girish K Extended release matrix tablets
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery

Also Published As

Publication number Publication date
NO20080399L (no) 2008-03-31
AU2006263338A1 (en) 2007-01-04
EA200800162A1 (ru) 2008-06-30
CA2613407A1 (en) 2007-01-04
CR9705A (es) 2008-10-30
TNSN07490A1 (en) 2009-03-17
US20090099154A1 (en) 2009-04-16
BRPI0613070A2 (pt) 2010-12-21
MX2008000084A (es) 2008-03-18
EP1912628A2 (en) 2008-04-23
JP2009500318A (ja) 2009-01-08
WO2007000779A2 (en) 2007-01-04
WO2007000779A3 (en) 2007-06-28
AU2006263338A2 (en) 2008-06-05
AR055070A1 (es) 2007-08-01
CN101212957A (zh) 2008-07-02

Similar Documents

Publication Publication Date Title
RS20070512A (en) Pharmaceutical sustained release compositionsand processes thereof
NO20081212L (no) Xantinderivater som selektive HM74A agonister
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
TW200738742A (en) Antiviral compounds
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
UA96277C2 (en) Benzimidazole derivatives
UA89394C2 (uk) Композиція оланзапіну або донепезилу, що розпадається при пероральному прийомі
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2007002635A3 (en) C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
NO20081844L (no) Terapeutiske forbindelser
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
TW200740814A (en) Compounds
TW200726758A (en) New pyridine analogues
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
SG171471A1 (en) New benzimidazole derivatives
TW200621773A (en) Bicyclononene derivatives
SI1817326T1 (sl) Industrijski postopek za pripravo gama-laktona 17-hidroksi-6-beta, 7-beta, 15-beta, 16-beta-bismetilen-3-okso 17-alfa pregn-4-en-21- karboksilne kisline in kljuäśni intermediati za ta postopek
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
TW200628468A (en) Bicyclononene derivatives
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.